Recent Update on the Development of PCSK9 Inhibitors for Hypercholesterolemia Treatment
出版年份 2022 全文链接
标题
Recent Update on the Development of PCSK9 Inhibitors for Hypercholesterolemia Treatment
作者
关键词
-
出版物
Journal of Medicinal Chemistry
Volume 65, Issue 23, Pages 15513-15539
出版商
American Chemical Society (ACS)
发表日期
2022-11-30
DOI
10.1021/acs.jmedchem.2c01290
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Development of small-molecule PCSK9 inhibitors for the treatment of hypercholesterolemia
- (2022) Shakir Ahamad et al. DRUG DISCOVERY TODAY
- Computational Design and Biological Evaluation of Analogs of Lupin Peptide P5 Endowed with Dual PCSK9/HMG-CoAR Inhibiting Activity
- (2022) Carmen Lammi et al. Pharmaceutics
- Engineered EGF-A Peptides with Improved Affinity for Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)
- (2021) Benjamin J. Tombling et al. ACS Chemical Biology
- New Insight Into Metformin-Induced Cholesterol-Lowering Effect Crosstalk Between Glucose and Cholesterol Homeostasis via ChREBP (Carbohydrate-Responsive Element-Binding Protein)-Mediated PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Regulation
- (2021) Die Hu et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Trans-Epithelial Transport, Metabolism and Biological Activity Assessment of the Multi-Target Lupin Peptide LILPKHSDAD (P5) and Its Metabolite LPKHSDAD (P5-Met)
- (2021) Carmen Lammi et al. Nutrients
- PCSK9: a view beyond the canonical cholesterol lowering impact
- (2021) Chiara Macchi et al. AMERICAN JOURNAL OF PATHOLOGY
- Increased Valency Improves Inhibitory Activity of Peptides Targeting Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)
- (2021) Benjamin J. Tombling et al. CHEMBIOCHEM
- In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates
- (2021) Kiran Musunuru et al. NATURE
- The emerging landscape of peptide-based inhibitors of PCSK9
- (2021) Benjamin J. Tombling et al. ATHEROSCLEROSIS
- PCSK9 Biology and Its Role in Atherothrombosis
- (2021) Cristina Barale et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Potent Lys Patch-Containing Stapled Peptides Targeting PCSK9
- (2021) Kévin Bourbiaux et al. JOURNAL OF MEDICINAL CHEMISTRY
- A Series of Novel, Highly Potent, and Orally Bioavailable Next-Generation Tricyclic Peptide PCSK9 Inhibitors
- (2021) Thomas J. Tucker et al. JOURNAL OF MEDICINAL CHEMISTRY
- Design of Organo-Peptides As Bipartite PCSK9 Antagonists
- (2020) Daniel J. Burdick et al. ACS Chemical Biology
- Advances in the molecular mechanisms of NLRP3 inflammasome activators and inactivators
- (2020) Dongling Liu et al. BIOCHEMICAL PHARMACOLOGY
- Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
- (2020) Kausik K. Ray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
- (2020) Frederick J. Raal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Naturally Occurring PCSK9 Inhibitors
- (2020) Maria Pia Adorni et al. Nutrients
- PCSK9Qβ-003 Vaccine Attenuates Atherosclerosis in Apolipoprotein E-Deficient Mice
- (2020) Danyu Wu et al. CARDIOVASCULAR DRUGS AND THERAPY
- Exploring Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Autoproteolysis Process by Molecular Simulations: Hints for Drug Design
- (2020) Jacopo Sgrignani et al. ChemMedChem
- Evolocumab, a PCSK9‐Monoclonal Antibody, Rapidly Reverses Coronary Artery Endothelial Dysfunction in People Living With HIV and People With Dyslipidemia
- (2020) Thorsten M. Leucker et al. Journal of the American Heart Association
- Regions of conformational flexibility in the proprotein convertase PCSK9 and design of antagonists for LDL cholesterol lowering
- (2020) Daniel Kirchhofer et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- PCSK9 and LRP5 in macrophage lipid internalization and inflammation
- (2020) Lina Badimon et al. CARDIOVASCULAR RESEARCH
- Novel Cyclic Tetramer Compounds as PCSK9 Inhibitors for Treating Metabolic Disorders
- (2020) Ram W. Sabnis ACS Medicinal Chemistry Letters
- Results of a 52 week open-label phase 2B study to assess long-term safety, immunogenicity and LDL-C efficacy of monthly dosing with LIB003 a novel anti-PCSK9 recombinant fusion protein
- (2020) T.A. Turner et al. ATHEROSCLEROSIS
- Bioactive Cyclization Optimizes the Affinity of a Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Peptide Inhibitor
- (2020) Benjamin J. Tombling et al. JOURNAL OF MEDICINAL CHEMISTRY
- Novel strategies to target PCSK9: beyond monoclonal antibodies
- (2019) Nabil G Seidah et al. CARDIOVASCULAR RESEARCH
- Biological Characterization of Computationally Designed Analogs of peptide TVFTSWEEYLDWV (Pep2-8) with Increased PCSK9 Antagonistic Activity
- (2019) Carmen Lammi et al. Scientific Reports
- CARDIOVASCULAR EVENTS WITH PCSK9 INHIBITORS: AN UPDATED META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS
- (2019) Manuela Casula et al. PHARMACOLOGICAL RESEARCH
- Improvement in arterial stiffness after short-term treatment with PCSK9 inhibitors
- (2019) A.F.G. Cicero et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities
- (2019) Magnus Bäck et al. Nature Reviews Cardiology
- 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease
- (2019) Donna K. Arnett et al. CIRCULATION
- Sub-optimal cholesterol response to initiation of statins and future risk of cardiovascular disease
- (2019) Ralph Kwame Akyea et al. HEART
- Proprotein Convertase Subtilisin/Kexin Type 9, Brain Cholesterol Homeostasis and Potential Implication for Alzheimer’s Disease
- (2019) Maria Pia Adorni et al. Frontiers in Aging Neuroscience
- Computationally Driven Structure Optimization, Synthesis, and Biological Evaluation of Imidazole-Based Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Inhibitors
- (2019) Carmen Lammi et al. JOURNAL OF MEDICINAL CHEMISTRY
- PCSK9-D374Y mediated LDL-R degradation can be functionally inhibited by EGF-A and truncated EGF-A peptides: An in vitro study
- (2019) Vincenza Valenti et al. ATHEROSCLEROSIS
- 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
- (2019) François Mach et al. EUROPEAN HEART JOURNAL
- Blood flow patterns regulate PCSK9 secretion via MyD88-mediated pro-inflammatory cytokines
- (2019) Shijie Liu et al. CARDIOVASCULAR RESEARCH
- 20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia
- (2019) Ilse K. Luirink et al. NEW ENGLAND JOURNAL OF MEDICINE
- The changing landscape of lipid-lowering therapy after the new ESC/EAS guidelines for the management of dyslipidaemias: Launching the era of triple hypolipidaemic therapy in very high risk patients
- (2019) Loukianos S. Rallidis ATHEROSCLEROSIS
- Diagnosing Resistance to a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor
- (2018) Michael D. Shapiro et al. ANNALS OF INTERNAL MEDICINE
- Anticalin® Proteins as Therapeutic Agents in Human Diseases
- (2018) Christine Rothe et al. BIODRUGS
- Therapeutic peptides: Historical perspectives, current development trends, and future directions
- (2018) Jolene L. Lau et al. BIOORGANIC & MEDICINAL CHEMISTRY
- PCSK9 regulates expression of scavenger receptors and ox-LDL uptake in macrophages
- (2018) Zufeng Ding et al. CARDIOVASCULAR RESEARCH
- Improved endothelial function after short-term therapy with evolocumab
- (2018) Guglielmo Maulucci et al. Journal of Clinical Lipidology
- Generation and Characterization of a Novel Small Biologic Alternative to Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Antibodies, DS-9001a, Albumin Binding Domain–Fused Anticalin Protein
- (2018) Yusuke Masuda et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Small Molecule Inhibitors of the PCSK9·LDLR Interaction
- (2018) Jaru Taechalertpaisarn et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- The Evolving Future of PCSK9 Inhibitors
- (2018) Robert S. Rosenson et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Development of vaccine for dyslipidemia targeted to a proprotein convertase subtilisin/kexin type 9 (PCSK9) epitope in mice
- (2018) Ryo Kawakami et al. PLoS One
- First Food-Derived Peptide Inhibitor of the Protein–Protein Interaction between Gain-of-Function PCSK9D374Y and the Low-Density Lipoprotein Receptor
- (2018) Giovanni Grazioso et al. JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
- Small molecules as inhibitors of PCSK9: Current status and future challenges
- (2018) Shengtao Xu et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- In utero CRISPR-mediated therapeutic editing of metabolic genes
- (2018) Avery C. Rossidis et al. NATURE MEDICINE
- PCSK9 inhibitors: clinical evidence and implementation
- (2018) Marc S. Sabatine Nature Reviews Cardiology
- Inhibition of PCSK9D374Y/LDLR Protein–Protein Interaction by Computationally Designed T9 Lupin Peptide
- (2018) Carmen Lammi et al. ACS Medicinal Chemistry Letters
- Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
- (2017) Brian A. Ference et al. EUROPEAN HEART JOURNAL
- The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice
- (2017) Christine Landlinger et al. EUROPEAN HEART JOURNAL
- PCSK9 deficiency reduces atherosclerosis, apolipoprotein B secretion, and endothelial dysfunction
- (2017) Hua Sun et al. JOURNAL OF LIPID RESEARCH
- Accelerated atherosclerosis development in C57Bl6 mice by overexpressing AAV-mediated PCSK9 and partial carotid ligation
- (2017) Sandeep Kumar et al. LABORATORY INVESTIGATION
- Discovery of a cryptic peptide-binding site on PCSK9 and design of antagonists
- (2017) Yingnan Zhang et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- A Highly Durable RNAi Therapeutic Inhibitor of PCSK9
- (2017) Kevin Fitzgerald et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
- (2017) Kausik K. Ray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Discovery of a cryptic peptide-binding site on PCSK9 and design of antagonists
- (2017) Yingnan Zhang et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- A Therapeutic Peptide Vaccine Against PCSK9
- (2017) Yajie Pan et al. Scientific Reports
- Cross-Talk Between PCSK9 and Damaged mtDNA in Vascular Smooth Muscle Cells: Role in Apoptosis
- (2016) Zufeng Ding et al. ANTIOXIDANTS & REDOX SIGNALING
- Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering
- (2016) Giuseppe Danilo Norata et al. CARDIOVASCULAR RESEARCH
- Knowing the Prevalence of Familial Hypercholesterolemia Matters: Table.
- (2016) Anne C. Goldberg et al. CIRCULATION
- The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis
- (2016) Jan Borén et al. CURRENT OPINION IN LIPIDOLOGY
- Disrupting the PCSK9/LDLR protein–protein interaction by an imidazole-based minimalist peptidomimetic
- (2016) Mattia Stucchi et al. ORGANIC & BIOMOLECULAR CHEMISTRY
- Lipoprotein(a)
- (2016) Sotirios Tsimikas Current Opinion in Endocrinology Diabetes and Obesity
- Heart Disease and Cancer Deaths — Trends and Projections in the United States, 1969–2020
- (2016) Hannah K. Weir et al. Preventing Chronic Disease
- Lupin Peptides Modulate the Protein-Protein Interaction of PCSK9 with the Low Density Lipoprotein Receptor in HepG2 Cells
- (2016) Carmen Lammi et al. Scientific Reports
- Hemodynamic Shear Stress via ROS Modulates PCSK9 Expression in Human Vascular Endothelial and Smooth Muscle Cells and Along the Mouse Aorta
- (2015) Zufeng Ding et al. ANTIOXIDANTS & REDOX SIGNALING
- A systematic literature review of the effect of carotid atherosclerosis on local vessel stiffness and elasticity
- (2015) Mari E. Boesen et al. ATHEROSCLEROSIS
- Antisense-mediated reduction of proprotein convertase subtilisin/kexin type 9 (PCSK9): a first-in-human randomized, placebo-controlled trial
- (2015) Eveline P. van Poelgeest et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Cross-talk between LOX-1 and PCSK9 in vascular tissues
- (2015) Zufeng Ding et al. CARDIOVASCULAR RESEARCH
- Modulating protein–protein interactions: the potential of peptides
- (2015) Laura Nevola et al. CHEMICAL COMMUNICATIONS
- Statin Intolerance
- (2015) David H. Fitchett et al. CIRCULATION
- Peptide therapeutics: current status and future directions
- (2015) Keld Fosgerau et al. DRUG DISCOVERY TODAY
- LDL-R promoting activity of peptides derived from human PCSK9 catalytic domain (153–421): Design, synthesis and biochemical evaluation
- (2015) Rasha H. Alghamdi et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9
- (2015) Sam J. L. van der Tuin et al. JOURNAL OF LIPID RESEARCH
- Local effects of human PCSK9 on the atherosclerotic lesion
- (2015) Ilaria Giunzioni et al. JOURNAL OF PATHOLOGY
- Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
- (2015) Jennifer G. Robinson et al. NEW ENGLAND JOURNAL OF MEDICINE
- GRP94 Regulates Circulating Cholesterol Levels through Blockade of PCSK9-Induced LDLR Degradation
- (2015) Steve Poirier et al. Cell Reports
- Constraining Cyclic Peptides To Mimic Protein Structure Motifs
- (2014) Timothy A. Hill et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Design and Synthesis of Truncated EGF-A Peptides that Restore LDL-R Recycling in the Presence of PCSK9 In Vitro
- (2014) Christina I. Schroeder et al. CHEMISTRY & BIOLOGY
- Mechanisms of Plaque Formation and Rupture
- (2014) Jacob Fog Bentzon et al. CIRCULATION RESEARCH
- Induction of Atherosclerosis in Mice and Hamsters Without Germline Genetic Engineering
- (2014) Martin Mæng Bjørklund et al. CIRCULATION RESEARCH
- Permanent Alteration of PCSK9 With In Vivo CRISPR-Cas9 Genome Editing
- (2014) Qiurong Ding et al. CIRCULATION RESEARCH
- Annexin A2 Reduces PCSK9 Protein Levels via a Translational Mechanism and Interacts with the M1 and M2 Domains of PCSK9
- (2014) Kévin Ly et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- LDL CHOLESTEROL REDUCTION WITH BMS-962476, AN ADNECTIN INHIBITOR OF PCSK9: RESULTS OF A SINGLE ASCENDING DOSE STUDY
- (2014) Evan A. Stein et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- LDL receptor knock-out mice show impaired spatial cognition with hippocampal vulnerability to apoptosis and deficits in synapses
- (2014) Shao-hua Wang et al. Lipids in Health and Disease
- Acute Kidney Injury During Therapy With an Antisense Oligonucleotide Directed Against PCSK9
- (2013) Eveline P. van Poelgeest et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Serum Proprotein Convertase Subtilisin/Kexin Type 9 and Cell Surface Low-Density Lipoprotein Receptor
- (2013) Hagai Tavori et al. CIRCULATION
- Heart Disease and Stroke Statistics—2014 Update
- (2013) Alan S. Go et al. CIRCULATION
- Identification of a Small Peptide That Inhibits PCSK9 Protein Binding to the Low Density Lipoprotein Receptor
- (2013) Yingnan Zhang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Low Density Lipoprotein Binds to Proprotein Convertase Subtilisin/Kexin Type-9 (PCSK9) in Human Plasma and Inhibits PCSK9-mediated Low Density Lipoprotein Receptor Degradation
- (2013) Tanja Kosenko et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial
- (2013) Kevin Fitzgerald et al. LANCET
- Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Can Mediate Degradation of the Low Density Lipoprotein Receptor-Related Protein 1 (LRP-1)
- (2013) Maryssa Canuel et al. PLoS One
- Gene silencing approaches for the management of dyslipidaemia
- (2013) Giuseppe Danilo Norata et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- The Future of Peptide-based Drugs
- (2012) David J. Craik et al. Chemical Biology & Drug Design
- Furin-cleaved Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Is Active and Modulates Low Density Lipoprotein Receptor and Serum Cholesterol Levels
- (2012) Michael T. Lipari et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Regulation of hepatic LDL receptors by mTORC1 and PCSK9 in mice
- (2012) Ding Ai et al. JOURNAL OF CLINICAL INVESTIGATION
- Calcium-Independent Inhibition of PCSK9 by Affinity-Improved Variants of the LDL Receptor EGF(A) Domain
- (2012) Yingnan Zhang et al. JOURNAL OF MOLECULAR BIOLOGY
- The biology and therapeutic targeting of the proprotein convertases
- (2012) Nabil G. Seidah et al. NATURE REVIEWS DRUG DISCOVERY
- Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels
- (2011) Nicola Ferri et al. ATHEROSCLEROSIS
- Identification of proprotein convertase substrates using genome-wide expression correlation analysis
- (2011) Hannu Turpeinen et al. BMC GENOMICS
- PCSK9 reduces the protein levels of the LDL receptor in mouse brain during development and after ischemic stroke
- (2011) Estelle Rousselet et al. JOURNAL OF LIPID RESEARCH
- Hyperlipidemia-Triggered Neutrophilia Promotes Early Atherosclerosis
- (2010) Maik Drechsler et al. CIRCULATION
- Regulatory Effects of Peptides from the Pro and Catalytic Domains of Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) on Low-Density Lipoprotein Receptor (LDL-R)
- (2010) H. Palmer-Smith et al. CURRENT MEDICINAL CHEMISTRY
- Strong induction of PCSK9 gene expression through HNF1α and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters
- (2010) Bin Dong et al. JOURNAL OF LIPID RESEARCH
- Subtilases: The superfamily of subtilisin-like serine proteases
- (2010) Roland J. Siezen et al. PROTEIN SCIENCE
- Antagonism of Secreted PCSK9 Increases Low Density Lipoprotein Receptor Expression in HepG2 Cells
- (2009) Markey C. McNutt et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Dissection of the Endogenous Cellular Pathways of PCSK9-induced Low Density Lipoprotein Receptor Degradation
- (2009) Steve Poirier et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The unique role of proprotein convertase subtilisin/kexin 9 in cholesterol homeostasis
- (2009) S. A. Mousavi et al. JOURNAL OF INTERNAL MEDICINE
- Overexpression of Low-Density Lipoprotein Receptor in the Brain Markedly Inhibits Amyloid Deposition and Increases Extracellular Aβ Clearance
- (2009) Jungsu Kim et al. NEURON
- PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide
- (2008) LiXin Shan et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- PCSK9 is required for the disposal of non-acetylated intermediates of the nascent membrane protein BACE1
- (2008) Mary Cabell Jonas et al. EMBO REPORTS
- Annexin A2 Is a C-terminal PCSK9-binding Protein That Regulates Endogenous Low Density Lipoprotein Receptor Levels
- (2008) Gaétan Mayer et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Molecular basis for LDL receptor recognition by PCSK9
- (2008) H. J. Kwon et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started